E-learning: MRD Negativity in Multiple Myeloma (MM)

Introduction to MM

About Multiple Myeloma (MM)
Introduction to MM
Incidence and prevalence of MM
The prognostic significance of minimal residual disease (MRD)
Evolution of MGUS to MM
Pathogenesis of MM
Types of MM therapy
Risk factors
Diagnosis
Stages and grading
MRD methods and sensitivity
MRD negativity-based treatment
Treatment Landscape For MM
Current treatment guidelines for MM
Newly diagnosed multiple myeloma (NDMM)
Relapsed/refractory multiple myeloma (RRMM)
Summary Of Clinical Trials Investigating MRD Status
MRD status as a surrogate endpoint for PFS
Transplant-eligible newly diagnosed MM
- CASSIOPEIA study
- GRIFFIN study
- MASTER study
- PETHEMA/GEM pooled analysis
Transplant-ineligible newly diagnosed MM
- MAIA study
- ALCYONE study
- Pooled analysis MAIA and ALCYONE
- CEPHEUS study
Relapsed/refractory (RR) MM
- CASTOR study
- POLLUX study
- Sustained MRD negativity predicts long-term outcomes in R/R MM (pooled analysis of CASTOR and POLLUX)
- APOLLO study
- ICARIA-MM and IKEMA studies
Prognostic value of MRD negativity by depth of response
Balancing disease status and the immune environment in MM
Future approaches and other emerging treatment strategies
Summary/Take Home Messages